Approved indication: Tavneos is approved as an adjunctive (add-on) therapy for adults with severe active ANCA-associated vasculitis (granulomatosis with polyangiitis or microscopic polyangiitis) and is used together with standard treatments such as rituximab or cyclophosphamide plus glucocorticoids; its safety and effectiveness are not established in people under 18 years of age.

Off-label or investigational uses: Avacopan (Tavneos) is being studied for other complement-mediated kidney diseases such as C3 glomerulopathy, but controlled trials have not shown clear benefit and these uses remain investigational rather than routine off-label treatment.

Efficacy expectations: In the main clinical trial, about 7 in 10 patients achieved remission by 6 months and roughly two-thirds maintained sustained remission at 1 year when Tavneos was added to standard therapy, with kidney function and relapse rates at least as good as high-dose oral steroid regimens and with substantially lower overall glucocorticoid exposure; many patients notice improvement in symptoms over the first few weeks to months, while full benefit on organ protection and relapse risk is assessed over many months.

Typical dosing and how to take it: For adults with ANCA-associated vasculitis, the recommended dose is 30 mg (three 10 mg capsules) taken by mouth twice daily with food, roughly 12 hours apart; capsules should be swallowed whole with water and not crushed, chewed, or opened.

Special dosing instructions: Your doctor may reduce the Tavneos dose to 30 mg once daily if you must take a strong CYP3A4 inhibitor (such as certain antifungal or HIV medicines), and the drug is generally not recommended in people with cirrhosis or severe hepatic impairment; no specific dose adjustment is usually required solely for reduced kidney function, but closer monitoring is often used in patients with significant kidney disease.

Missed dose and overdose guidance: If you miss a dose, skip the missed dose and take your next dose at the regular scheduled time without taking extra capsules to "make up" the dose; in case of suspected overdose, seek emergency medical attention or contact Poison Control right away at 1-800-222-1222.

Common side effects: The most frequent side effects (occurring in at least a few percent of patients) include nausea, headache, high blood pressure, diarrhea, vomiting, rash, fatigue or tiredness, upper stomach/abdominal pain, dizziness, increased blood creatinine, and tingling or "pins and needles" sensations; these are often mild to moderate, tend to occur in the first weeks or months, and may improve as treatment continues.

Serious side effects needing urgent medical attention: Tavneos can cause serious infections (such as pneumonia or urinary tract infections that may require hospitalization), liver injury (with symptoms such as yellowing of the skin or eyes, dark urine, severe fatigue, right-sided abdominal pain, or easy bruising), hepatitis B reactivation in people with prior infection, and severe allergic reactions including angioedema (sudden swelling of the face, lips, tongue, or throat, trouble breathing, or hives); anyone with these warning signs should stop the drug and seek emergency care right away.

Warnings and precautions: Tavneos is generally avoided in people with active serious infections or with cirrhosis or uncontrolled chronic liver disease, and liver tests are checked before starting and then regularly (especially during the first 6 months); patients are screened for hepatitis B and may need antiviral prophylaxis and monitoring if they have evidence of past or current infection, and clinicians often monitor kidney function, blood counts, and blood pressure during therapy.

Pregnancy, breastfeeding, and age limits: It is not known if Tavneos harms an unborn baby or passes into breast milk, so its use in pregnancy or while breastfeeding is based on a careful risk–benefit discussion, with effective contraception usually recommended; the medicine is approved only for adults, and safety and effectiveness in children have not been established.

Overall safety profile and reporting: In large studies, overall rates of serious adverse events with Tavneos plus standard therapy were similar to high-dose steroid regimens, but steroid-related toxicities were lower because less glucocorticoid was needed; patients should promptly tell their healthcare provider about any side effects, and side effects can be reported to the FDA MedWatch program (1-800-FDA-1088 or the MedWatch website) or to the manufacturer using the phone number in the Medication Guide.

Prescription and OTC drug interactions: Strong or moderate CYP3A4 inducers (such as rifampin, carbamazepine, phenytoin, and St John’s wort) can markedly lower Tavneos levels and may make it ineffective, so they are usually avoided; strong CYP3A4 inhibitors (including itraconazole, ketoconazole, clarithromycin, and certain HIV protease inhibitors) can roughly double avacopan exposure, so the Tavneos dose is typically reduced to 30 mg once daily, and because Tavneos is a moderate CYP3A4 inhibitor it can raise blood levels of other CYP3A4 substrates (for example some statins, benzodiazepines, and calcineurin inhibitors like cyclosporine or tacrolimus), which may require dose adjustments and closer monitoring.

Food, alcohol, and supplements: Tavneos should be taken with food to ensure good absorption, and patients are advised to avoid grapefruit and grapefruit juice because they can significantly increase avacopan levels and the risk of side effects; alcohol has no specific documented interaction but should be used cautiously, particularly in people with liver disease or on other hepatotoxic medications, and herbal products or supplements that affect the immune system or liver function should only be used after review with a clinician.

Conditions and co-medications requiring extra caution: Use of Tavneos is generally avoided or undertaken with great caution in people with active serious infections, a history of hepatitis B without appropriate antiviral management, uncontrolled chronic liver disease or cirrhosis, recurrent severe infections, or markedly abnormal liver tests, and it should be used carefully alongside other immunosuppressive drugs because of additive infection risk.

Monitoring needs: Before and during therapy, clinicians typically obtain liver function tests, hepatitis B serology, and periodic checks of kidney function, blood counts, and blood pressure, and they review all prescription, over-the-counter, and herbal products regularly to adjust doses or avoid interacting drugs when necessary.

Q: What is Tavneos prescribed for?
A: Tavneos is prescribed as an oral add-on medicine for adults with severe active ANCA-associated vasculitis (granulomatosis with polyangiitis or microscopic polyangiitis), used together with standard treatments such as rituximab or cyclophosphamide and glucocorticoids.

Q: How long does it take for Tavneos to start working?
A: Some people begin to notice symptom improvement within the first several weeks, but clinical trials assessed remission at 6 and 12 months, so Tavneos is typically used as part of a long-term regimen to control disease and protect organs.

Q: Will I still need steroids if I am taking Tavneos?
A: Yes, Tavneos is used in combination with standard therapy including glucocorticoids, but adding Tavneos can allow for lower total steroid doses over time compared with traditional high-dose steroid regimens alone.

Q: What should I do if I miss a dose of Tavneos?
A: If you miss a dose, do not take an extra dose; simply skip the missed dose and take your next scheduled dose at the usual time.

Q: Are there foods or drinks I should avoid while taking Tavneos?
A: You should take each dose with food and avoid grapefruit or grapefruit juice, which can raise Tavneos levels, and you should check with your healthcare provider before using herbal supplements, especially those that affect the immune system or the liver.

Q: Is Tavneos safe in pregnancy or while breastfeeding?
A: There is not enough information to know how safe Tavneos is during pregnancy or breastfeeding, so people who are pregnant, planning pregnancy, or nursing should discuss alternative options and contraception with their clinician before starting or continuing this medicine.

Storage: Store Tavneos capsules at room temperature (68°F to 77°F / 20°C to 25°C) in the original container, tightly closed, away from excess heat, moisture, and light, and out of reach of children and pets.

Disposal: Do not flush unused or expired capsules; use community medicine take-back programs when available or ask your pharmacist how to dispose of them safely (for example, mixing with an unappealing substance, sealing in a bag or container, and discarding in household trash).